Sales and Marketing Best Practices
Best Practices, LLC has conducted extensive research in the field of Sales and Marketing. Browse through and sample our published Sales and Marketing research in the topics below:
| |  | Enhancing Brand Performance Through Sales & Marketing Excellence
Benchmark and identify winning strategies and practices of successful brands in highly competitive pharmaceutical markets. Insights were gathered through surveys and in-depth interviews with veteran brand marketing and sales executives at 12 leading drug companies. The participants represent 20 key brands.
These insights provide an excellence benchmark against which companies can compare their own brand promotion functions. Specifically, companies can learn about the field force promotion activities, successful marketing strategies and tactics, and levels of promotional resource support. This executive presentation covers reach and frequency goals for meetings and other activities. In addition, it provides numerous insights, observations and best practices from interviewed executives.
Best Practices in Pharmaceutical Alliances and Co-Promotions
Improve the quality and efficiency of sales partnerships by excelling in the vital practices of co-promotions. Focus areas include deal making, relationship management, and sales and marketing management. This Best Practices Benchmarking® Report contains numerous findings that will enable companies in the pharmaceutical and biotechnology sector to understand the critical success factors of alliances and co-promotions. Moreover, the findings contained in this report will enable your company and strategic partners to move knowledgeably forward toward the objective of developing its own alliance and co-promotion system.
If you are interested in this report, check out "Profitable Partnerships: Developing Excellence in Alliances."
Growing Lone Products into Broad-Based Brands: Best Practices in Trademark and Branding Development
Top brand teams in the pharmaceutical industry discuss how to best manage the complexities of branding and launching multiple indications of an active ingredient. According to Food and Drug Administration (FDA) statistics, about two thirds of all new products launched in the pharmaceutical marketplace over a recent 11-year period grew from existing molecular entities. That is to say, of 1035 new drugs approved between 1989 and 2000, more than 650 of them were products derived from existing active ingredients. They represented new indications, new formulations, new patient niches and new markets. This powerful statistic underscores the dramatic need for pharmaceutical companies to better master the development and marketing of chemical compounds as lifecycle franchises. By franchise, executives mean that one compound will have many forms and formulations that maximize its economic and therapeutic potential.
|
|